N-(2,6-dinitrophenyl)glycine | 1084-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,6-dinitrophenyl)glycine
• 英文别名: N-(2,6-Dinitro-phenyl)-glycin；2-(2,6-Dinitroanilino)acetic acid
• CAS: 1084-44-2
• 化学式: C₈H₇N₃O₆
• 分子量: 241.16
• InChiKey: MJFOKIUVTFLXJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  141
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-(2,6-dinitrophenyl)glycine 在 硫酸 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 1-hydroxy-5-nitroquinoxaline-2,3(1H,4H)-dione
  参考文献：
  名称：

  o-Nitroaniline derivatives. Part 14.1,2 Cyclisations leading to benzimidazole N-oxides, N-hydroxybenzimidazolones and N-hydroxyquinoxaline-2,3-diones: a mechanistic borderline

  摘要：

  基诱导的 N-(o-硝基苯)甘氨酸衍生物（含有额外取代基的腈 9 或酯 13）环化反应表现出异常，类似于 N-(o-硝基苯)天冬氨酸类似物所涉及的反应。这些腈被转化为 N-羟基苯并咪唑酮 10，而酯被转化为 1-羟基喹咯啉-2,3(1H,4H)二酮 14 和 2,2′-二氨基偶氮苯衍生物 15，而不是预期的 2-取代 1H-苯并咪唑 3-氧化物 11 和 16，或 2-未取代的类似物 17。探索了所有这些反应通过一个共同的 2,1,4-苯并噁二嗪中间体 18 进行的可能性。

  DOI：

  10.1039/a607378f
• 作为产物：
  描述：

  2,6-二硝基氯苯 在 potassium fluoride 、 碳酸氢钠 作用下， 以 二甲基亚砜 为溶剂， 生成 N-(2,6-dinitrophenyl)glycine
  参考文献：
  名称：

  Wilshire,J.F.K., Australian Journal of Chemistry, 1967, vol. 20, p. 2809 - 2811

  摘要：

  DOI：

文献信息

• FromN-(dinitrophenyl) amino acids to benzimidazoleN-oxides. Synthesis, kinetics and mechanism
  作者：Elba I. Buján、María Laura Salum

  DOI：10.1002/poc.1017

  日期：2006.3

  Several benzimidazole N-oxide derivatives were synthesized in very good yields by heating under reflux the corresponding N-(2,4- or 2,6-dinitrophenyl) amino acid derivative with NaOH in 60% 1,4-dioxane–H2O. The N-oxides obtained from glycine and α- and β-alanine derivatives lost the carboxylic group. The observed rate constant for the reaction of N-(2,4-dinitrophenyl) glycine (2a) in 10% 1,4-dioxane–H2O

  通过在60％1,4-二恶烷–H 2 O中用NaOH加热回流相应的N-（2,4-或2,6-二硝基苯基）氨基酸衍生物，可以以很高的收率合成几种苯并咪唑N-氧化物衍生物。由甘氨酸以及α-和β-丙氨酸衍生物获得的N-氧化物失去了羧基。N-（2,4-二硝基苯基）甘氨酸（2a）在10％1,4-二恶烷-H 2 O中反应生成5-硝基-1 H-苯并咪唑-3-氧化物（4a）的观察到的速率常数在[NaOH]上是一阶；二阶速率常数为k N = 1.7×10 -3 M -1  s -1。提出的机理包括形成N-亚烷基2-亚硝基苯胺型中间体作为速率确定步骤。版权所有©2006 John Wiley＆Sons，Ltd.
• PENTADIENAMIDE DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2050734A1

  公开（公告）日：2009-04-22

  The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R3 represents a hydrogen atom or is combined together with R4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R5, R6, and R7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种由式(I)表示的戊二烯酰胺衍生物:(其中R1代表取代或未取代的芳基或取代或未取代的芳香族杂环基；R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物；R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基；R4代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物，或与R3及其相邻的氮原子结合形成取代或未取代的杂环基；R5、R6和R7可以相同也可以不同，每个代表氢原子或甲基)或其药学上可接受的盐等。
• PENTADIENAMIDE DERIVATIVES
  申请人：NAKASATO Yoshisuke

  公开号：US20090203667A1

  公开（公告）日：2009-08-13

  The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R 1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R 3 represents a hydrogen atom or is combined together with R 4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R 4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R 3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R 5 , R 6 , and R 7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种由以下公式（I）表示的五二烯酰胺衍生物：（其中，R1代表取代或未取代的芳基或取代或未取代的芳香杂环基；R2代表取代或未取代的芳基，取代或未取代的芳香杂环基，取代或未取代的杂环螺环基或类似物；R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基；R4代表取代或未取代的芳基，取代或未取代的芳香杂环基，取代或未取代的杂环螺环基或类似物，或与R3及其相邻的氮原子结合形成取代或未取代的杂环基；R5、R6和R7可以相同也可以不同，每个代表氢原子或甲基）或其药学上可接受的盐等。
• [EN] ABAD INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'ABAD
  申请人：[en]UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS

  公开号：WO2023026060A1

  公开（公告）日：2023-03-02

  The present invention concerns Amyloid Binding Alcohol Dehydrogenase (ABAD) inhibitors (I) or (II) that interact non- competitively with nicotinamide adenine dinucleotide + H (NADH). Inhibition of ABAD is useful in the treatment or prophylaxis of disease, including Alzheimer's disease (AD) and cancer. Accordingly, the present invention also concerns ABAD inhibitors for use as a medicament, specifically for use in the treatment of Alzheimer's disease and/or cancer.
• Wilshire,J.F.K., Australian Journal of Chemistry, 1967, vol. 20, p. 2809 - 2811
  作者：Wilshire,J.F.K.

  DOI：——

  日期：——